184 related articles for article (PubMed ID: 36826844)
21. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
Mok J; Adeleke MO; Brown A; Magee CG; Firman C; Makahamadze C; Jassil FC; Marvasti P; Carnemolla A; Devalia K; Fakih N; Elkalaawy M; Pucci A; Jenkinson A; Adamo M; Omar RZ; Batterham RL; Makaronidis J
JAMA Surg; 2023 Oct; 158(10):1003-1011. PubMed ID: 37494014
[TBL] [Abstract][Full Text] [Related]
22. Verapamil and beta cell function in adults with recent-onset type 1 diabetes.
Ovalle F; Grimes T; Xu G; Patel AJ; Grayson TB; Thielen LA; Li P; Shalev A
Nat Med; 2018 Aug; 24(8):1108-1112. PubMed ID: 29988125
[TBL] [Abstract][Full Text] [Related]
23. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.
Raz I; Avron A; Tamir M; Metzger M; Symer L; Eldor R; Cohen IR; Elias D
Diabetes Metab Res Rev; 2007 May; 23(4):292-8. PubMed ID: 17124720
[TBL] [Abstract][Full Text] [Related]
24. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
Gitelman SE; Gottlieb PA; Rigby MR; Felner EI; Willi SM; Fisher LK; Moran A; Gottschalk M; Moore WV; Pinckney A; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; Ding L; Bluestone JA; Ehlers MR;
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):306-16. PubMed ID: 24622416
[TBL] [Abstract][Full Text] [Related]
25. Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes.
Waibel M; Wentworth JM; So M; Couper JJ; Cameron FJ; MacIsaac RJ; Atlas G; Gorelik A; Litwak S; Sanz-Villanueva L; Trivedi P; Ahmed S; Martin FJ; Doyle ME; Harbison JE; Hall C; Krishnamurthy B; Colman PG; Harrison LC; Thomas HE; Kay TWH;
N Engl J Med; 2023 Dec; 389(23):2140-2150. PubMed ID: 38055252
[TBL] [Abstract][Full Text] [Related]
26. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Pescovitz MD; Greenbaum CJ; Krause-Steinrauf H; Becker DJ; Gitelman SE; Goland R; Gottlieb PA; Marks JB; McGee PF; Moran AM; Raskin P; Rodriguez H; Schatz DA; Wherrett D; Wilson DM; Lachin JM; Skyler JS;
N Engl J Med; 2009 Nov; 361(22):2143-52. PubMed ID: 19940299
[TBL] [Abstract][Full Text] [Related]
27. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
28. A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Alpha-1 Antitrypsin (AAT) (Glassia
Lebenthal Y; Brener A; Hershkovitz E; Shehadeh N; Shalitin S; Lewis EC; Elias D; Haim A; Barash G; Loewenthal N; Zuckerman-Levin N; Stein M; Tov N; Rachmiel M
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795482
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial.
Yan X; Li X; Liu B; Huang J; Xiang Y; Hu Y; Tang X; Zhang Z; Huang G; Xie Z; Zhou H; Liu Z; Wang X; Leslie RD; Zhou Z
Signal Transduct Target Ther; 2023 Apr; 8(1):158. PubMed ID: 37076476
[TBL] [Abstract][Full Text] [Related]
30. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.
Ann Intern Med; 1998 Apr; 128(7):517-23. PubMed ID: 9518395
[TBL] [Abstract][Full Text] [Related]
31. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
Orban T; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Greenbaum CJ; Marks JB; Monzavi R; Moran A; Raskin P; Rodriguez H; Russell WE; Schatz D; Wherrett D; Wilson DM; Krischer JP; Skyler JS;
Lancet; 2011 Jul; 378(9789):412-9. PubMed ID: 21719096
[TBL] [Abstract][Full Text] [Related]
32. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.
Haller MJ; Gitelman SE; Gottlieb PA; Michels AW; Rosenthal SM; Shuster JJ; Zou B; Brusko TM; Hulme MA; Wasserfall CH; Mathews CE; Atkinson MA; Schatz DA
J Clin Invest; 2015 Jan; 125(1):448-55. PubMed ID: 25500887
[TBL] [Abstract][Full Text] [Related]
33. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes.
Rother KI; Brown RJ; Morales MM; Wright E; Duan Z; Campbell C; Hardin DS; Popovic J; McEvoy RC; Harlan DM; Orlander PR; Brod SA
Diabetes Care; 2009 Jul; 32(7):1250-5. PubMed ID: 19564474
[TBL] [Abstract][Full Text] [Related]
34. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N; Hagopian W; Ludvigsson J; Jain SM; Wahlen J; Ferry RJ; Bode B; Aronoff S; Holland C; Carlin D; King KL; Wilder RL; Pillemer S; Bonvini E; Johnson S; Stein KE; Koenig S; Herold KC; Daifotis AG;
Lancet; 2011 Aug; 378(9790):487-97. PubMed ID: 21719095
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes.
Buckingham B; Beck RW; Ruedy KJ; Cheng P; Kollman C; Weinzimer SA; DiMeglio LA; Bremer AA; Slover R; Tamborlane WV; ;
Diabetes Care; 2013 Dec; 36(12):4030-5. PubMed ID: 24130350
[TBL] [Abstract][Full Text] [Related]
36. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus.
Gabbay MA; Sato MN; Finazzo C; Duarte AJ; Dib SA
Arch Pediatr Adolesc Med; 2012 Jul; 166(7):601-7. PubMed ID: 22751874
[TBL] [Abstract][Full Text] [Related]
37. INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED): a study protocol for a randomised, double-blind, placebo-controlled clinical trial in children and adolescents with recent-onset type 1 diabetes.
Pedersen IB; Kjolby M; Hjelholt AJ; Madsen M; Christensen AR; Adolfsen D; Hjelle JS; Kremke B; Støvring H; Jessen N; Vestergaard ET; Kristensen K; Frobert O
BMJ Open; 2024 Jul; 14(6):e084808. PubMed ID: 38950997
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal.
Pozzilli P; Raz I; Peled D; Elias D; Avron A; Tamir M; Eren R; Dagan S; Cohen IR
Diabetes Care; 2014; 37(5):1384-91. PubMed ID: 24408401
[TBL] [Abstract][Full Text] [Related]
39. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
[TBL] [Abstract][Full Text] [Related]
40. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
Keymeulen B; van Maurik A; Inman D; Oliveira J; McLaughlin R; Gittelman RM; Roep BO; Gillard P; Hilbrands R; Gorus F; Mathieu C; Van de Velde U; Wisniacki N; Napolitano A
Diabetologia; 2021 Feb; 64(2):313-324. PubMed ID: 33145642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]